From Around The Web Here Are 20 Amazing Infographics About Personalize…
Adrian
2024.09.22 01:18
6
0
본문
Personalized Depression Treatment
Traditional therapy and medication are not effective for a lot of patients suffering from depression. The individual approach to treatment could be the answer.
Cue is an intervention platform that converts passively acquired sensor data from smartphones into customized micro-interventions for improving mental health. We examined the most effective-fitting personalized ML models for each individual, using Shapley values, in order to understand their features and predictors. This revealed distinct features that were deterministically changing mood over time.
Predictors of Mood
Depression is among the leading causes of mental illness.1 However, only about half of people suffering from the condition receive treatment1. In order to improve outcomes, clinicians need to be able to recognize and treat patients with the highest chance of responding to particular treatments.
The ability to tailor depression treatments is one method of doing this. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit the most from certain treatments. They make use of sensors for mobile phones as well as a voice assistant that incorporates artificial intelligence as well as other digital tools. Two grants worth more than $10 million will be used to discover the biological treatment for depression and behavioral factors that predict response.
The majority of research on predictors for depression treatment effectiveness has focused on the sociodemographic and clinical aspects. These include demographic variables like age, sex and education, clinical characteristics including the severity of symptoms and comorbidities and biological treatment for depression indicators such as neuroimaging and genetic variation.
While many of these aspects can be predicted by the data in medical records, only a few studies have used longitudinal data to explore predictors of mood in individuals. They have not taken into account the fact that mood can vary significantly between individuals. Therefore, it is essential to create methods that allow the identification of different mood predictors for each person and treatments effects.
The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to develop algorithms that can systematically identify different patterns of behavior and emotion that are different between people.
In addition to these modalities the team developed a machine-learning algorithm to model the changing variables that influence each person's mood. The algorithm combines these personal characteristics into a distinctive "digital phenotype" for each participant.
The digital phenotype was associated with CAT DI scores, a psychometrically validated symptom severity scale. The correlation was not strong however (Pearson r = 0,08; P-value adjusted by BH 3.55 10 03) and varied widely among individuals.
Predictors of symptoms
Depression is a leading cause of disability around the world1, but it is often not properly diagnosed and treated. In addition the absence of effective treatments and stigma associated with depressive disorders prevent many from seeking treatment.
To aid in the development of a personalized treatment plan in order to provide a more personalized treatment, identifying factors that predict the severity of symptoms is crucial. However, the methods used to predict symptoms are based on the clinical interview, which is unreliable and only detects a small number of features associated with depression.2
Machine learning can be used to blend continuous digital behavioral phenotypes that are captured through smartphone sensors and an online mental health tracker (the Computerized Adaptive Testing depression treatment plan cbt (like it) Inventory, CAT-DI) with other predictors of severity of symptoms could improve diagnostic accuracy and increase the effectiveness of treatment for depression treatment resistant. Digital phenotypes can provide continuous, high-resolution measurements and capture a wide range of unique behaviors and activity patterns that are difficult to record through interviews.
The study involved University of California Los Angeles (UCLA) students with moderate to severe depressive symptoms. enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29, which was developed under the UCLA Depression Grand Challenge. Participants were routed to online assistance or in-person clinics according to the severity of their depression. Those with a CAT-DI score of 35 or 65 were allocated online support with a peer coach, while those with a score of 75 were sent to in-person clinics for psychotherapy.
At the beginning, participants answered the answers to a series of questions concerning their personal characteristics and psychosocial traits. The questions covered age, sex and education, financial status, marital status as well as whether they divorced or not, the frequency of suicidal ideas, intent or attempts, and the frequency with which they consumed alcohol. The CAT-DI was used to assess the severity of depression-related symptoms on a scale from zero to 100. CAT-DI assessments were conducted each week for those who received online support and once a week for those receiving in-person care.
Predictors of the Reaction to Treatment
The development of a personalized depression treatment is currently a major research area and many studies aim at identifying predictors that allow clinicians to identify the most effective medication for each patient. Pharmacogenetics, for instance, is a method of identifying genetic variations that affect how the human body metabolizes drugs. This allows doctors select medications that are most likely to work for each patient, reducing the time and effort needed for trials and errors, while eliminating any adverse negative effects.
Another approach that is promising is to create predictive models that incorporate information from clinical studies and neural imaging data. These models can be used to determine which variables are most likely to predict a specific outcome, like whether a medication will help with symptoms or mood. These models can be used to determine a patient's response to treatment that is already in place which allows doctors to maximize the effectiveness of their current therapy.
A new era of research employs machine learning techniques like supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables and improve the accuracy of predictive. These models have been shown to be effective in predicting outcomes of treatment for example, the response to antidepressants. These models are getting more popular in psychiatry, and it is expected that they will become the standard for future clinical practice.
The study of depression's underlying mechanisms continues, as well as predictive models based on ML. Recent findings suggest that depression is linked to dysfunctions in specific neural networks. This theory suggests that a individualized treatment for depression will be based on targeted treatments that restore normal function to these circuits.
Internet-based-based therapies can be an effective method to achieve this. They can offer an individualized and tailored experience for patients. For instance, one study found that a web-based program was more effective than standard treatment in improving symptoms and providing the best quality of life for those with MDD. Furthermore, a randomized controlled study of a personalised approach to treating depression treatment medications showed an improvement in symptoms and fewer side effects in a significant percentage of participants.
Predictors of adverse effects
A major obstacle in individualized depression treatment is predicting which antidepressant medications will have the least amount of side effects or none at all. Many patients have a trial-and error method, involving several medications being prescribed before settling on one that is safe and effective. Pharmacogenetics offers a fascinating new method for an effective and precise method of selecting antidepressant therapies.
A variety of predictors are available to determine which antidepressant to prescribe, such as gene variants, patient phenotypes (e.g. sexual orientation, gender or ethnicity) and comorbidities. To identify the most reliable and accurate predictors for a particular treatment, randomized controlled trials with larger numbers of participants will be required. This is because the detection of moderators or interaction effects could be more difficult in trials that consider a single episode of treatment per person instead of multiple episodes of treatment over a period of time.
In addition, predicting a patient's response will likely require information about the comorbidities, symptoms profiles and the patient's personal experience of tolerability and effectiveness. Presently, only a handful of easily measurable sociodemographic and clinical variables seem to be reliable in predicting the severity of MDD like age, gender race/ethnicity, BMI and the presence of alexithymia, and the severity of depressive symptoms.
Many issues remain to be resolved when it comes to the use of pharmacogenetics for depression treatment. First it is necessary to have a clear understanding of the genetic mechanisms is required as well as a clear definition of what is a reliable indicator of treatment response. Additionally, ethical issues like privacy and the appropriate use of personal genetic information, should be considered with care. In the long run pharmacogenetics can be a way to lessen the stigma that surrounds mental health treatment and to improve the outcomes of those suffering with depression. Like any other psychiatric treatment, it is important to take your time and carefully implement the plan. For now, the best method is to offer patients an array of effective depression medication options and encourage them to talk with their physicians about their experiences and concerns.
Traditional therapy and medication are not effective for a lot of patients suffering from depression. The individual approach to treatment could be the answer.
Cue is an intervention platform that converts passively acquired sensor data from smartphones into customized micro-interventions for improving mental health. We examined the most effective-fitting personalized ML models for each individual, using Shapley values, in order to understand their features and predictors. This revealed distinct features that were deterministically changing mood over time.
Predictors of Mood
Depression is among the leading causes of mental illness.1 However, only about half of people suffering from the condition receive treatment1. In order to improve outcomes, clinicians need to be able to recognize and treat patients with the highest chance of responding to particular treatments.
The ability to tailor depression treatments is one method of doing this. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit the most from certain treatments. They make use of sensors for mobile phones as well as a voice assistant that incorporates artificial intelligence as well as other digital tools. Two grants worth more than $10 million will be used to discover the biological treatment for depression and behavioral factors that predict response.
The majority of research on predictors for depression treatment effectiveness has focused on the sociodemographic and clinical aspects. These include demographic variables like age, sex and education, clinical characteristics including the severity of symptoms and comorbidities and biological treatment for depression indicators such as neuroimaging and genetic variation.
While many of these aspects can be predicted by the data in medical records, only a few studies have used longitudinal data to explore predictors of mood in individuals. They have not taken into account the fact that mood can vary significantly between individuals. Therefore, it is essential to create methods that allow the identification of different mood predictors for each person and treatments effects.
The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to develop algorithms that can systematically identify different patterns of behavior and emotion that are different between people.
In addition to these modalities the team developed a machine-learning algorithm to model the changing variables that influence each person's mood. The algorithm combines these personal characteristics into a distinctive "digital phenotype" for each participant.
The digital phenotype was associated with CAT DI scores, a psychometrically validated symptom severity scale. The correlation was not strong however (Pearson r = 0,08; P-value adjusted by BH 3.55 10 03) and varied widely among individuals.
Predictors of symptoms
Depression is a leading cause of disability around the world1, but it is often not properly diagnosed and treated. In addition the absence of effective treatments and stigma associated with depressive disorders prevent many from seeking treatment.
To aid in the development of a personalized treatment plan in order to provide a more personalized treatment, identifying factors that predict the severity of symptoms is crucial. However, the methods used to predict symptoms are based on the clinical interview, which is unreliable and only detects a small number of features associated with depression.2
Machine learning can be used to blend continuous digital behavioral phenotypes that are captured through smartphone sensors and an online mental health tracker (the Computerized Adaptive Testing depression treatment plan cbt (like it) Inventory, CAT-DI) with other predictors of severity of symptoms could improve diagnostic accuracy and increase the effectiveness of treatment for depression treatment resistant. Digital phenotypes can provide continuous, high-resolution measurements and capture a wide range of unique behaviors and activity patterns that are difficult to record through interviews.
The study involved University of California Los Angeles (UCLA) students with moderate to severe depressive symptoms. enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29, which was developed under the UCLA Depression Grand Challenge. Participants were routed to online assistance or in-person clinics according to the severity of their depression. Those with a CAT-DI score of 35 or 65 were allocated online support with a peer coach, while those with a score of 75 were sent to in-person clinics for psychotherapy.
At the beginning, participants answered the answers to a series of questions concerning their personal characteristics and psychosocial traits. The questions covered age, sex and education, financial status, marital status as well as whether they divorced or not, the frequency of suicidal ideas, intent or attempts, and the frequency with which they consumed alcohol. The CAT-DI was used to assess the severity of depression-related symptoms on a scale from zero to 100. CAT-DI assessments were conducted each week for those who received online support and once a week for those receiving in-person care.
Predictors of the Reaction to Treatment
The development of a personalized depression treatment is currently a major research area and many studies aim at identifying predictors that allow clinicians to identify the most effective medication for each patient. Pharmacogenetics, for instance, is a method of identifying genetic variations that affect how the human body metabolizes drugs. This allows doctors select medications that are most likely to work for each patient, reducing the time and effort needed for trials and errors, while eliminating any adverse negative effects.
Another approach that is promising is to create predictive models that incorporate information from clinical studies and neural imaging data. These models can be used to determine which variables are most likely to predict a specific outcome, like whether a medication will help with symptoms or mood. These models can be used to determine a patient's response to treatment that is already in place which allows doctors to maximize the effectiveness of their current therapy.
A new era of research employs machine learning techniques like supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to blend the effects of several variables and improve the accuracy of predictive. These models have been shown to be effective in predicting outcomes of treatment for example, the response to antidepressants. These models are getting more popular in psychiatry, and it is expected that they will become the standard for future clinical practice.
The study of depression's underlying mechanisms continues, as well as predictive models based on ML. Recent findings suggest that depression is linked to dysfunctions in specific neural networks. This theory suggests that a individualized treatment for depression will be based on targeted treatments that restore normal function to these circuits.
Internet-based-based therapies can be an effective method to achieve this. They can offer an individualized and tailored experience for patients. For instance, one study found that a web-based program was more effective than standard treatment in improving symptoms and providing the best quality of life for those with MDD. Furthermore, a randomized controlled study of a personalised approach to treating depression treatment medications showed an improvement in symptoms and fewer side effects in a significant percentage of participants.
Predictors of adverse effects
A major obstacle in individualized depression treatment is predicting which antidepressant medications will have the least amount of side effects or none at all. Many patients have a trial-and error method, involving several medications being prescribed before settling on one that is safe and effective. Pharmacogenetics offers a fascinating new method for an effective and precise method of selecting antidepressant therapies.
A variety of predictors are available to determine which antidepressant to prescribe, such as gene variants, patient phenotypes (e.g. sexual orientation, gender or ethnicity) and comorbidities. To identify the most reliable and accurate predictors for a particular treatment, randomized controlled trials with larger numbers of participants will be required. This is because the detection of moderators or interaction effects could be more difficult in trials that consider a single episode of treatment per person instead of multiple episodes of treatment over a period of time.
In addition, predicting a patient's response will likely require information about the comorbidities, symptoms profiles and the patient's personal experience of tolerability and effectiveness. Presently, only a handful of easily measurable sociodemographic and clinical variables seem to be reliable in predicting the severity of MDD like age, gender race/ethnicity, BMI and the presence of alexithymia, and the severity of depressive symptoms.
Many issues remain to be resolved when it comes to the use of pharmacogenetics for depression treatment. First it is necessary to have a clear understanding of the genetic mechanisms is required as well as a clear definition of what is a reliable indicator of treatment response. Additionally, ethical issues like privacy and the appropriate use of personal genetic information, should be considered with care. In the long run pharmacogenetics can be a way to lessen the stigma that surrounds mental health treatment and to improve the outcomes of those suffering with depression. Like any other psychiatric treatment, it is important to take your time and carefully implement the plan. For now, the best method is to offer patients an array of effective depression medication options and encourage them to talk with their physicians about their experiences and concerns.
댓글목록 0